Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
Want to see AARD full AI Analyst Report?
AARD Stock Chart & Stats
$5.23
--
Market closed
$5.23
--
Day’s Range― - ―
52-Week Range$3.35 - $17.94
Previous CloseN/A
VolumeN/A
Average Volume (3M)164.05K
Market Cap
$75.92M
Enterprise Value$27.57M
Total Cash (Recent Filing)$91.20M
Total Debt (Recent Filing)$336.00K
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Aug 19, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding21,816,385
10 Day Avg. Volume142,906
30 Day Avg. Volume164,047
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.28
Enterprise Value/Market Cap0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.51K
Enterprise Value/Ebitda-0.37
Forecast
1Y Price Target
$5.00Price Target Upside-4.40% Downside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-3.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage & Positive EquityVery low debt and a restoration to positive equity provide structural financial resilience for a development-stage biotech. This reduces near-term insolvency risk and preserves strategic optionality to fund trials or pursue partnerships while clinical outcomes are resolved.
Flexible Equity Financing CapacityAn on‑demand $150M equity program gives management a durable financing tool to periodically raise capital under favorable conditions. That flexibility lowers the risk of emergency financings and supports sustained development spending or opportunistic partnerships over the medium term.
Cash Runway & Proactive Data PlanReported cash runway into mid‑2027 coupled with management's plan to unblind trial data provides time to assess program viability and make evidence‑based decisions. This preserves strategic options (reroute, redesign, partner) rather than forcing hasty actions.
Bears Say
FDA Full Clinical Hold On Lead ProgramA full FDA clinical hold is a material, structural setback: it pauses enrollment and dosing, may require additional safety data or protocol changes, delays regulatory timelines, and raises the risk the program will need costly extra studies or could be terminated.
Pre-revenue With Widening Operating LossesThe company remains pre‑commercial with accelerating operating losses, meaning there's no revenue buffer to absorb R&D spend. Over the medium term this magnifies reliance on external financing and increases the stakes of clinical outcomes for long‑term viability.
Large And Growing Cash BurnSubstantial negative operating cash flow converts paper losses into real runway depletion. Continued high burn, especially with the clinical hold, elevates dilution or cost‑cutting risk and constrains strategic flexibility absent partnerships or timely financings.
Aardvark Therapeutics, Inc. News
AARD FAQ
What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?
Aardvark Therapeutics, Inc. lowest stock price was $3.35 and its highest was $17.94 in the past 12 months.
What is Aardvark Therapeutics, Inc.’s market cap?
Aardvark Therapeutics, Inc.’s market cap is $75.92M.
When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?
Aardvark Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 69 days.
How were Aardvark Therapeutics, Inc.’s earnings last quarter?
Aardvark Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.877 by -$0.113.
Is Aardvark Therapeutics, Inc. overvalued?
According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Overvalued.
Does Aardvark Therapeutics, Inc. pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
What is Aardvark Therapeutics, Inc.’s EPS estimate?
Aardvark Therapeutics, Inc.’s EPS estimate is -0.86.
How many shares outstanding does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has 21,816,385 shares outstanding.
What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?
Aardvark Therapeutics, Inc. reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.877. Following the earnings report the stock price went down -4.924%.
Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aardvark Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.00 (-4.40% Downside)
$5.00 (-4.40% Downside)
Blogger Sentiment
Neutral
AARD Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 10.9%
Last 30 Days ▼ 10.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.43%
12-Months-Change
Fundamentals
Return on Equity
-61.71%
Trailing 12-Months
Asset Growth
-37.21%
Trailing 12-Months
Company Description
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
AARD Stock 12 Month Forecast
Average Price Target
$5.00
▼(-4.40% Downside)
Technical Analysis
Ownership Overview
14.98% Insiders
4.49% Mutual Funds
26.69% Other Institutional Investors
48.13% Public Companies and
Individual Investors